As the non-muscle invasive space is carved up, Aura tries to seize part of it.

Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.

At least 15 dual-payload ADCs will be discussed.

Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.

On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.

In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.

Ikena, Senti and others look to clinical presentations at AACR.